100 listed sites: Belgium (4); Canada (9); France (4); Germany (5); Japan (17); Mexico (6); Netherlands (2); Poland (13); Spain (6); United States (34) - 02 Nov `23Povorcitinib tablets for nonsegmental vitiligo

Povorcitinib tablets for nonsegmental vitiligo

Official title: A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo

Status: Closed to new participants

Description:

Incyte Corporation enrolled about 467 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People age 18 and older may qualify. The study is underway but is no longer accepting new participants.

Start date: November 29, 2023

Completion date: February 24, 2027

Organizer: Incyte Corporation

Contact: Incyte Medical Monitor

Link: https://clinicaltrials.gov/study/NCT06113445

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Povorcitinib tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Can Ayurveda help with vitiligo?

    Ayurveda, the ancient Indian system of holistic medicine, focuses on balancing body energies (Doshas) and improving digestion. While it offers a valuable perspective on "whole-b...

  • Is it Bitiligo? Vitaligo? Veteligo?

    There are so many different ways that people try and spell or even pronounce Vitiligo. Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vitag...

  • What is vitiligo?

    Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Contr...